Nearly all the patients with severe SCD treated with the gene-editing therapy reni-cel remained free of VOEs for up to two ...

Editas Medicine (NASDAQ:EDIT – Free Report) had its price objective trimmed by Evercore ISI from $7.00 to $5.00 in a report ...

A Cambridge-based biotechnology company announced Thursday its plans to lay off about 65% of its workforce over the next ...

Fintel reports that on December 16, 2024, JP Morgan downgraded their outlook for Editas Medicine (NasdaqGS:EDIT) from Neutral ...

On Friday, Editas Medicine Inc (EDIT) stock saw a decline, ending the day at $1.44 which represents a decrease of $-0.45 or -23.81% from the prior close of $1.89. The stock opened at $1.75 and touched ...

Editas stock falls as it ends development of reni-cel for SCD and TDT following failed attempts to find a commercial partner. It plans to cut workforce by 65%.

Anavex Life Sciences Corp (AVXL) is expected to report $-0.16 for 4Q. Avalon Advanced Materials Inc (AVL.T) is expected to report for 4Q. Centene Corp (CNC) is expected to report for Full year.

Here are today's Five Things You Need to Know today in Boston business news, including Editas job cuts, CVS shares plunge, Moderna's name in the sky, the Boston tea party and the best birthday gift ...

Stifel Nicolaus cut shares of Editas Medicine (NASDAQ:EDIT – Free Report) from a buy rating to a hold rating in a report ...

Moderna contended in documents that it needs the larger, higher sign because it's blocked from anywhere other than right in front of the building by trees in the public park betwe ...

Morgan Stanley analyst Terence Flynn has maintained their neutral stance on EDIT stock, giving a Hold rating yesterday.Pick the best stocks ...

Truist and Stifel downgraded Editas Medicine Inc (NASDAQ:EDIT) to "hold" from "buy". While Truist removed its price target ...